• Mutation; HGNC; 583; APC; Simple; p.Arg976fs*9 (c.2926_2927insA); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=25846456; Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (PubMed=25846456; Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (Cosmic-CLP; DepMap).
  

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=9698466; DOI=10.1006/gyno.1998.5039
Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecol. Oncol. 70:13-16(1998)

PubMed=10433623; DOI=10.1093/jnci/91.15.1327
Furlong M.T., Hough C.D., Sherman-Baust C.A., Pizer E.S., Morin P.J.
Evidence for the colonic origin of ovarian cancer cell line SW626.
J. Natl. Cancer Inst. 91:1327-1328(1999)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=20106510; DOI=10.1016/j.ygyno.2009.12.002
Byron S.A., Gartside M.G., Wellens C.L., Goodfellow P.J., Birrer M.J., Campbell I.G., Pollock P.M.
FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Gynecol. Oncol. 117:125-129(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25846456; DOI=10.3892/ijo.2015.2951
Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol. 46:2389-2398(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)